Back to discover
Disease

Ehlers-Danlos Syndrome

Late-stage therapeutic developmentEmerging research
MeSHEhlers-Danlos Syndrome
1
Publications
10
Clinical trials
12
Associated genes
2017
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2030.
Upcoming Milestones
Major developments
Upcoming trial readoutWorth watching
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
Results expected Q1 20302025-10-22
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
10
All trials
3
Active
4
Late-stage
4
Completed
Recently completed

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.

Phase 3 · Completed · Assistance Publique - Hôpitaux de Paris

IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients

N/A · Completed · Bispebjerg Hospital

Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome

Phase 4 · Completed · Assistance Publique - Hôpitaux de Paris

A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome

Phase 2 · Completed · National Human Genome Research Institute (NHGRI)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

American journal of medical genetics. Part C, Seminars in medical genetics · 2017 · 334 cites
Recent publications

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

American journal of medical genetics. Part C, Seminars in medical genetics · 2017 · 334 cites
Leading journals1
  • American journal of medical genetics. Part C, Seminars in medical genetics1
Leading researchers7
  • Berglund B1
  • Castori M1
  • Cohen H1
  • Grahame R1
  • Kazkaz H1
  • Levy H1
  • Tinkle B1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

COL5A10.64COL1A20.62COL3A10.59B3GALT60.56PLOD10.52TNXB0.52COL5A20.46B4GALT70.42CHST140.42PRDM50.41ZNF4690.40THBS20.37

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.

Identifiers
MeSHEhlers-Danlos Syndrome
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.